Patient,
Hospital,
Ministry,
UGE,
Patent,
Quarter,
FDA,
Traction,
United European Gastroenterology,
Gastrointestinal bleeding,
Physician,
OTCQB,
History,
EVS The most fulfilling aspect of the new system is seeing the device support emergent cases in GI bleeding and seeing how sites can adopt the technology with no onsite support.
Key Points:
- The most fulfilling aspect of the new system is seeing the device support emergent cases in GI bleeding and seeing how sites can adopt the technology with no onsite support.
- At the end of the first quarter of 2024, the Company successfully implemented a limited U.S. commercial launch of the Pure-Vu® EVS Gastro and Gen 4 Colon system.
- The Company reported $4.9 million in cash and cash equivalents as of March 31, 2024.
- This balance includes the fully funded credit facility with Kreos Capital, which has approximately $2.3 million due and outstanding as of March 31, 2024.
“We believe the EVS Gastro system opens up significant new market opportunities for our technology, especially in the emergent setting of upper GI bleeding.
Key Points:
- “We believe the EVS Gastro system opens up significant new market opportunities for our technology, especially in the emergent setting of upper GI bleeding.
- Initiated over the last quarter, a limited U.S. commercial launch of the Pure-Vu® EVS Gastro and Gen 4 Colon system.
- Financial Results for the Quarter and Year Ended December 31, 2023
The Company reported revenue of $64,000 for the fourth quarter 2023, compared to $109,000 for the same period last year.
- This balance includes the fully funded credit facility with Kreos Capital, which has approximately $2.3 million due and outstanding as of December 31, 2023.
Retrieved on:
Thursday, February 22, 2024
As part of this transaction, the investor agreed to exercise the existing Series B common stock purchase warrant (which was originally issued in December 2023 and had an exercise price of $1.50 per share) at a revised exercise price of $0.925 per share.
Key Points:
- As part of this transaction, the investor agreed to exercise the existing Series B common stock purchase warrant (which was originally issued in December 2023 and had an exercise price of $1.50 per share) at a revised exercise price of $0.925 per share.
- The shares of common stock issuable upon exercise of the warrant were registered pursuant to an effective registration statement on Form S-1 (No.
- The transaction is expected to close no later than February 26, 2024, subject to satisfaction of customary closing conditions.
- The Company intends to use the net proceeds from the exercise for working capital and general corporate purposes.
Retrieved on:
Wednesday, February 21, 2024
This latest patent covers the automated management of pressure for irrigation and self-purging feature of the latest generation of the Pure-Vu system.
Key Points:
- This latest patent covers the automated management of pressure for irrigation and self-purging feature of the latest generation of the Pure-Vu system.
- This capability is key to enhancing the physician’s experience using the Pure-Vu, by avoiding procedure delays due to clogs,” commented Mark Pomeranz, Chief Executive Officer.
- This latest patent application is a continuation of U.S. patent applications Ser.
- Inpatient endoscopy on patients admitted to the hospital can be a difficult endeavor to get a quality procedure in a timely manner due to debris in the GI tract.
Retrieved on:
Friday, February 16, 2024
Key Points:
- The adjourned Special Meeting will reconvene on March 7, 2024 at 9:30 a.m. Eastern Time at www.cstproxy.com/motusgi/sm2024.
- The original record date of December 20, 2023 remains the same for the adjourned Special Meeting.
- The Company has adjourned the Special Meeting to allow stockholders additional time to vote.
- The proposal set forth in the Proxy Statement will be voted upon at the adjourned Special Meeting to be held on March 7, 2024.
Retrieved on:
Tuesday, January 30, 2024
Manuscript,
United European Gastroenterology,
History,
MOTS,
Patient,
BCS,
FDA,
Motus,
UGE,
Hospital,
Medical device The Company’s Pure-Vu System is an FDA-approved and CE-certified bowel cleansing system (BCS) intended to increase visualization in inadequately prepared colons by offering intraprocedural cleansing.
Key Points:
- The Company’s Pure-Vu System is an FDA-approved and CE-certified bowel cleansing system (BCS) intended to increase visualization in inadequately prepared colons by offering intraprocedural cleansing.
- “We are excited to see the positive results from this European study published in the UGE Journal, further building upon the extensive portfolio of study data and user experiences for the second generation Pure-Vu System.
- This study concluded that adequate bowel cleaning can be achieved in patients with a history of inadequate bowel preparation by using the Pure-Vu System.
- The study enrolled a total of 44 patients with previous poor bowel preparation (BBPS
Retrieved on:
Tuesday, December 19, 2023
The Series B warrants will have an exercise price of $1.50 per share, will be exercisable immediately, and will expire eighteen months from the initial issuance date.
Key Points:
- The Series B warrants will have an exercise price of $1.50 per share, will be exercisable immediately, and will expire eighteen months from the initial issuance date.
- The closing of the offering is expected to occur on or about December 21, 2023, subject to the satisfaction of customary closing conditions.
- The Company intends to use the net proceeds of this offering for working capital and other general corporate purposes.
- The offering is being made only by means of a prospectus forming part of the effective registration statement.
Retrieved on:
Monday, November 13, 2023
Ministry,
Food,
MDR,
Mortality,
CE marking,
Research,
FDA,
Hematochezia,
R,
Gastroenterology,
Medical device,
Retail,
Health “The past several months was an exciting period for the Company, as we executed against our strategy on several fronts.
Key Points:
- “The past several months was an exciting period for the Company, as we executed against our strategy on several fronts.
- Financial Results for the Third Quarter Ended September 30, 2023
The Company reported revenue of $86,000 for the third quarter 2023, compared to $278,000 for the same period last year.
- Share data is on a split adjusted basis resulting from the Company’s reverse stock split effective as of November 2, 2023.
- This balance included the fully funded credit facility with Kreos Capital, which has approximately $9.2 million due and outstanding as of September 30, 2023.
Retrieved on:
Friday, November 10, 2023
Associate,
Esophagus,
Stomach,
Assistant professor,
University,
University of Minnesota,
Risk,
Gastroparesis,
Mortality,
Patient,
Research,
FDA,
Hematochezia,
Blood,
MD,
Intubation,
Motus,
Suction,
Medical device,
Pharmaceutical industry,
Medicine FORT LAUDERDALE, Fla., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company focused on improving endoscopic outcomes and experiences, announced today that the Pure-Vu® EVS Gastro was successfully used in the first procedure since receiving FDA clearance. The case was completed by Dr. Brian Hanson, Gastroenterologist and Associate Professor of Medicine, University of Minnesota.
Key Points:
- “It is exciting to clear the first procedure milestone so soon after receiving FDA clearance.
- We look to forward to implementing the planned U.S. market introduction of the Pure-Vu EVS Gastro.
- I was able to normally retroflex the scope with the Pure-Vu EVS Gastro attached, and use irrigation to clear the field of view,” commented Dr. Hanson.
- Upper GI bleeds occurred in the U.S. at a rate of approximately 400,000 cases per year in 2019, according to iData Research Inc.
Retrieved on:
Wednesday, November 1, 2023
FORT LAUDERDALE, Fla., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company focused on improving endoscopic outcomes and experiences, announced today that it will effect a 1-for-15 reverse stock split of its outstanding common stock.
Key Points:
- FORT LAUDERDALE, Fla., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company focused on improving endoscopic outcomes and experiences, announced today that it will effect a 1-for-15 reverse stock split of its outstanding common stock.
- As a result of the reverse stock split, every fifteen pre-split shares of common stock outstanding will become one share of common stock.
- The reverse stock split will not change the authorized number of shares of the Company’s common stock.
- The reverse stock split will affect all stockholders uniformly and will not alter any stockholder’s percentage interest in the Company’s equity, except to the extent that the reverse stock split results in some stockholders owning a fractional share.
